Rationale for CDR132L, an antisense inhibitor of miR-132, for a novel therapy for ventricular remodelling after myocardial infarction
Por:
Aimo, A, Egea, OI, Bayes-Genis, A, Passino, C and Emdin, M
Publicada:
1 oct 2021
Resumen:
Filiaciones:
Aimo, A:
St Anna Sch Adv Studies, Pisa, Italy
:
Germans Trias & Pujol Hosp, Badalona, Spain
:
Germans Trias & Pujol Hosp, Badalona, Spain
Passino, C:
St Anna Sch Adv Studies, Pisa, Italy
Emdin, M:
St Anna Sch Adv Studies, Pisa, Italy
|